Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.

In the KATHERINE trial, whose results are reported by von Minckwitz et al. in this issue of the Journal (pages 617–28), 1486 patients with human epidermal growth factor receptor 2 (HER2)–positive early-stage breast cancer who had residual invasive cancer after preoperative chemotherapy plus..